Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2016 to 31 July 2016 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) 2016/C 490/08
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Not the law itself: Notice
Address https://gelex.eu/eli/EU/notice/oj/C/2016/490/08@2016-07-01/en
Contents
Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted Date of the decision Name of the medicinal product Holder of the marketing authorization Number of the entry in the Community Register Date of notification 29.7.2016 Fluenz Tetra MedImmune, LLC Lagelandseweg 78, NL-6545 CG Nijmegen, Nederland EU/1/13/887 2.8.2016 29.7.2016 Nimenrix Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom EU/1/12/767 3.8.2016 29.7.2016 Zontivity Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom EU/1/14/976 2.8.2016 Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact: European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom